A few randomized phase 3 trials have shown that combining PD-1 or programmed cell death ligand 1 (PD-L1) inhibitors with VEGF inhibitors and chemotherapy enhances antitumor activity and provides a PFS benefit for patients with advanced EGFR-mutated NSCLC who progressed after receiving EGFR TKI therapy. Here, PDCD1 is linked to non-small cell lung carcinoma.